Hopkins scientists link human papillomavirus (HPV) to head and neck cancer

May 02, 2000

Researchers at the Johns Hopkins School of Medicine and School of Hygiene and Public Health have found the sexually transmitted human papillomavirus (HPV) to be a likely cause of certain cancers of the head and neck and also an indicator of improved survival. Their findings are reported in the May 3, 2000, issue of the Journal of the National Cancer Institute.

The investigators studied tumors of 253 patients, ages 17 to 91, with newly diagnosed or recurring squamous cell head and neck cancer. HPV was detected in 62, or 25 percent, of the tumors and, of the HPV-positive tumors, 90 percent contained a high-risk, tumor-promoting form of the virus known as HPV-16. Somewhat unexpectedly, perhaps, those with HPV-positive tumors were 60 percent less likely to die from their head and neck cancer than those with HPV-negative tumors, according to the researchers. The data provide strong evidence that HPVs may be the cause of a defined subset of head and neck cancers, particularly those of the oropharynx (tonsils and throat), and this association with HPV infection also is linked to a markedly improved prognosis. While they currently cannot explain the improved survival, follow-up of participants revealed that the average survival of patients with HPV-positive tumors was 91 months or more but 76 months among patients with HPV-negative tumors. Other factors contributing to poor prognosis included advanced disease, age, and heavy alcohol consumption.

"These data suggest that HPV-positive head and neck cancers may comprise a distinct molecular, clinical, and pathologic disease very different from other types of the disease," says the Oncology Center's Maura L. Gillison, M.D., lead author of the study.

Squamous cell head and neck cancer is a disease largely attributable to environmental exposures-primarily tobacco and alcohol use. Fifteen to 20 percent of these cancers, however, occur in non-smokers and non-drinkers. "In this study, those with HPV-positive tumors in the oropharynx were light- or non-drinkers and non-smokers. We believe that HPV infection of the upper airway may be the cause of tumor development in this group of people," says Gillison. The researchers believe HPV causes the formation of head and neck cancers by producing two HPV-associated oncoproteins or growth-promoting proteins known as E6 and E7, which, in turn, inactivate the p53 and Rb tumor suppressor genes. They are planning a clinical trial of a cancer vaccine used for HPV-associated cervical cancers in these HPV-positive head and neck cancers. The vaccine would be given prior to standard therapy with surgery and/or radiation therapy.

"Although HPV DNA has been detected in head and neck cancers for sometime, its role in cancer development and the means by which HPV is transmitted to the upper airway has remained unclear," says one of the study's senior investigators, David Sidransky, M.D., professor of otolaryngology and oncology.

Although HPV presence in head and neck cancers has not yet been convincingly tied to specific sexual practices, HPV infection in head and neck cancer patients has been linked to the number of sexual partners in other studies, according to the researchers. "All of the evidence points to viral presence preceding disease progression," says Keerti V. Shah, M.D., Dr.P.H., professor of molecular microbiology and immunology.

An estimated 31,000 people in the United States are diagnosed each year with cancer of the oral cavity and pharynx. An additional 8,500 die each year from the disease. HPV is a sexually transmitted virus most recognized for its association with cervical and other genital squamous cell cancers.
-end-
In addition to Gillison, Sidransky, and Shah, other participants in this research include Wayne M. Koch, M.D., Randolph B. Capone, M.D., Michael Spafford, M.D., William H.Westra, M.D., Li Wu, Marianna L. Zahurak, M.S., Richard W. Daniel, B.S., Michael Viglione, M.D., and David E. Symer, M.D., Ph.D.

The study was funded by the National Institutes of Health and a Clinical Oncology Research Career Development Program grant.

Related Web site: The Johns Hopkins Oncology Center: http://www.hopkins.cancercenter.jhmi.edu

Media Contact: Vanessa Wasta 410-955-1287
Email: wastava@jhmi.edu

Johns Hopkins Medical Institutions' news releases are available on an EMBARGOED basis on
EurekAlert at http://www.eurekalert.org
Newswise at http://www.newswise.com
and from the Office of Communications and Public Affairs' direct e-mail news release service. To enroll, call 410-955-4288 or send e-mail to bsimpkins@jhmi.edu.

On a POST-EMBARGOED basis find them at http://hopkins.med.jhu.edu, Quadnet at http://www.quad-net.com and ScienceDaily at http://www.sciencedaily.com.

Johns Hopkins Medicine

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.